Journal: Mediators of Inflammation

Article Title: Intraoperative Peritoneal Interleukin-6 Concentration Changes in Relation to the High-Mobility Group Protein B1 and Heat Shock Protein 70 Levels in Children Undergoing Cholecystectomy

doi: 10.1155/2020/9613105

Figure Lengend Snippet: HMGB1 and HSP70 concentration in peritoneal lavage fluid of children at the beginning and at the end of laparoscopic and open cholecystectomy.

Article Snippet: HSP70 concentration was evaluated using a Biorbyt Human heat shock proteins (HSP70) ELISA kit (Catalogue No. Orb397059) in compliance with the manufacturer's instructions.

Techniques: Concentration Assay

Journal: Journal of Korean Neurosurgical Society

Article Title: S100ß, Matrix Metalloproteinase-9, D-dimer, and Heat Shock Protein 70 Are Serologic Biomarkers of Acute Cerebral Infarction in a Mouse Model of Transient MCA Occlusion

doi: 10.3340/jkns.2017.0200

Figure Lengend Snippet: Plasma HSP70 concentration in all groups. HSP70 concentration increases significantly in both infarction groups (p=0.001) when compared to that of the sham group (A); however, there is no correlation between HSP70 concentration and infarct area (r=0.174, p=0.406; b) or neurological score (r=0.138, p=0.510; c). * p <0.05. HSP70 : heat shock protein 70, McAO : middle cerebral artery occlusion.

Article Snippet: The plasma concentrations of S100β, MMP-9, D-dimer, and HSP70 were calculated using mouse protein S100β (CSB-EL-0206643MO; CUSABIO, Wuhan, China), mouse total MMP-9 (MMPT90; R&D Systems, Minneapolis, MN, USA), mouse D-dimer (E03D0224; BlueGene, Shanghai, China), and mouse HSP70 (CSB-E08311m; CUSABIO) ELISA kits.

Techniques: Clinical Proteomics, Concentration Assay

Journal: Journal of Korean Neurosurgical Society

Article Title: S100ß, Matrix Metalloproteinase-9, D-dimer, and Heat Shock Protein 70 Are Serologic Biomarkers of Acute Cerebral Infarction in a Mouse Model of Transient MCA Occlusion

doi: 10.3340/jkns.2017.0200

Figure Lengend Snippet: Sensitivity and specificity of the biomarkers. MMP-9 and HSP70 both have an AUc of 1. S100β has an AUc of 0.98. The AUc for D-dimer is 0.58. MMP-9 : matrix metalloproteinase-9, HSP70 : heat shock protein 70, AUc : the area under the receiver operating characteristic curve.

Article Snippet: The plasma concentrations of S100β, MMP-9, D-dimer, and HSP70 were calculated using mouse protein S100β (CSB-EL-0206643MO; CUSABIO, Wuhan, China), mouse total MMP-9 (MMPT90; R&D Systems, Minneapolis, MN, USA), mouse D-dimer (E03D0224; BlueGene, Shanghai, China), and mouse HSP70 (CSB-E08311m; CUSABIO) ELISA kits.

Techniques:

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Dynamics of plasma DAMP levels in advanced lung cancer patients during the first cycle of systemic anticancer therapy. (A) Time course of the fold change in plasma concentrations (relative to baseline) of HMGB1, CRT, HSP70, annexin A1, and histone H3 in individual patients. Plasma samples were collected before and on days 3 and 8 after the onset of the first cycle as well as before the onset of the second cycle of treatment. (B) Fold change in the plasma levels of HMGB1, CRT, HSP70, annexin A1, and histone H3 during the first treatment cycle relative to baseline. Data are means + SEM. The P values for differences in mean values were determined by repeated-measures ANOVA. (C) Comparison of baseline values and maximum values after the onset of the first cycle of treatment for the fold change in plasma levels of the five DAMPs. The numbers of patients showing a >2-fold increase were 34, 34, 24, 5, and 3 for HMGB1, CRT, HSP70, annexin A1, and histone H3, respectively. CRT and histone H3 were undetectable at baseline in 10 and 97 patients, respectively, and these patients were excluded from the analysis. The P values for differences in mean values were determined with the paired t test. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; SEM, standard error of the mean; ANOVA, analysis of variance.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics, Comparison

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Association between the maximum fold change in plasma DAMP levels relative to baseline and clinical response. The maximum fold change in HMGB1 (A), CRT (B), HSP70 (C), or annexin A1 (D) levels is shown as the mean + SEM for patients classified according to tumor response. The numbers of patients who showed a CR, PR, SD or PD according to RECIST criteria were 1, 43, 63, and 13, respectively; one patient not evaluable by RECIST criteria was excluded from the analysis. CRT was undetectable at baseline in seven patients with a PR, in two with SD, and in one with PD, and these patients were also excluded from the analysis. The P values for differences in mean values were determined by one-way ANOVA. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; ANOVA, analysis of variance.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Maximum fold changes in plasma DAMP concentrations according to anticancer treatment modality. The maximum fold change in HMGB1 (A), CRT (B), HSP70 (C), or annexin A1 (D) levels is shown as the mean + SEM for patients with a CR (n=1) or a PR (n=43). Treatment modalities included platinum doublet chemotherapy (n=22), single-agent chemotherapy (n=3), CCRT (n=11), and EGFR- or ALK-TKIs (n=8). CRT was undetectable at baseline in four patients receiving platinum doublet chemotherapy, one receiving single-agent chemotherapy, and two receiving CCRT, and these patients were excluded from the analysis. The P values for differences in mean values were determined by one-way ANOVA. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70; SEM, standard error of the mean; CR, complete response; PR, partial response; CCRT, concurrent chemoradiotherapy; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; ANOVA, analysis of variance.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics

Journal: Translational Lung Cancer Research

Article Title: Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

doi: 10.21037/tlcr-21-92

Figure Lengend Snippet: Correlation analysis for maximum fold changes in plasma DAMP concentrations. (A,B,C,D,E,F) Correlation analysis for HMGB1 and either CRT (A), HSP70 (B), or annexin A1 (C), for CRT and either HSP70 (D) or annexin A1 (E), or for HSP70 and annexin A1 (F) is shown. The correlation coefficient (r) and corresponding P values are indicated. CRT was undetectable at baseline in 10 patients, and these patients were excluded from the analysis. (G) Venn diagram for the numbers of patients showing a >2-fold increase in the plasma levels of HMGB1, CRT, or HSP70 during the first treatment cycle. DAMP, damage-associated molecular pattern; HMGB1, high-mobility group box 1; CRT, calreticulin; HSP70, heat shock protein 70.

Article Snippet: The plasma levels of CRT (#ELH-CALR-1; RayBiotech, Peachtree Corners, GA), HSP70 (#KE00059; Proteintech, Tokyo, Japan), and annexin A1 (#EK1745; Boster Biological Technology, Pleasanton, CA) were similarly quantified with ELISA kits.

Techniques: Clinical Proteomics

Journal: PloS one

Article Title: Biological responses of three-dimensional cultured fibroblasts by sustained compressive loading include apoptosis and survival activity.

doi: 10.1371/journal.pone.0104676

Figure Lengend Snippet: Figure 5. The secretions of HSP90a, HA, and PGE2 into cell culture medium were increased by compressive loading. Fibroblasts were seeded to collagen sponge and incubated for 24 h. And then they were subjected to 0, 50, 100, or 200 mmHg compression for 6 h. Culture supernatants were collected after 6 h loading experiments. The level of each substance (A: HSP90a, B: HA, C: PGE2) was measured by ELISA. A value of concentration was normalized by WST-1 value. The results are represented as the mean 6 SEM (error bars) of five experiments. Statistical analysis was performed using the Dunnett’s multiple test between non-loaded group and each of loaded group, and statistical significance was taken as p,0.05. A value of p was expressed as: *; p,0.05, **; p,0.01, and ***; p,0.001. doi:10.1371/journal.pone.0104676.g005

Article Snippet: HSP90a concentration was measured using the Rat Heat Shock Protein 90a ELISA kit (CUSABIO BIOTECH, Wuhan, China).

Techniques: Cell Culture, Incubation, Enzyme-linked Immunosorbent Assay, Concentration Assay